Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The FUTURE GB Trial has received OCTRU Green Light approval and is now open to recruitment!

Future GB logo


FUTURE-GB, an NIHR EME funded study, has opened with Southmead Hospital in Bristol as the first recruiting site.  Glioblastoma (GB) is the most common primary brain tumour and is incurable -with a poor prognosis for most patients. FUTURE-GB is a 2-stage trial, looking at the use of additional imaging technologies before and during adult glioblastoma surgery to improve patient outcomes and quality of life. Stage 1 of the trial is an IDEAL IIB study, with each patient receiving the additional imaging to ensure standardisation of practice with the technologies at each recruiting site. Stage 2 is the full randomised controlled trial, recruiting 357 participants from 15 neurosurgical centres across the UK. The whole trial will recruit for 33 months, and patient quality of life will be assessed for up to 2 years.

Similar stories

WHiTE Four trial results!


The WHiTE Four trial has now published its results in The Bone & Joint journal.

ARCADIAN trial opens to recruitment!


The ARCADIAN trial has received OCTRU Green Light approval and has now begun to open sites to recruitment!

HOPE-e study resumes recruitment of women with painful osteoarthritis in the hand


Researchers in Oxford are looking to recruit women who have painful osteoarthritis in joints of their hands, after resuming a study that was paused due to the COVID crisis.

HUSH trial opens to recruitment!


The HUSH trial has received OCTRU Green Light approval and is now open to recruitment!

Oxford researchers start new trial on the use of anti-TNF to treat Covid-19 in care homes

Main OCTRU Trials

Researchers at the University of Oxford are starting a new study to explore the effectiveness of the anti-tumour necrosis factor (anti-TNF) drug adalimumab as a treatment for patients with COVID-19 in the community, especially care homes. The AVID-CC trial, which will be conducted by Oxford Clinical Trials Research Unit (OCTRU), will enrol up to 750 patients from community care settings throughout the UK.

Operation Ouch!


CBBC's Operation Ouch have been helping to raise awareness of participation in clinical trials for children.